Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · December 31, 2022

Pembrolizumab for Patients With Non-Hodgkin Lymphoma Who Were Ineligible for or Failed Auto-HCT

Leukemia and Lymphoma


Additional Info

Disclosure statements are available on the authors' profiles:

Leukemia and Lymphoma
Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study
Leukemia and Lymphoma 2022 Nov 18;[EPub Ahead of Print], J Kuruvilla, P Armand, M Hamadani, J Kline, CH Moskowitz, D Avigan, JD Brody, V Ribrag, AF Herrera, F Morschhauser, A Kanate, PL Zinzani, J Bitran, H Ghesquieres, SJ Schuster, M Farooqui, P Marinello, NL Bartlett

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading